bioMerieux ended 2021 on a healthy note, with impressive sales and profitability, driven by promising dynamics across segments. This also resulted in impressive dividend growth. While 2022 guidance was on the weaker side – due to fading COVID-19 testing tailwinds, and increasing costs (partly also due to post-pandemic normalisation), it wasn’t a big surprise. While our estimates could reset marginally lower, the sell-off in recent months opens an attractive opportunity, also with respect to M&A ....

02 Mar 2022
Healthy 2021; weak 2022 guidance, but it isn’t an investment case spoiler

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy 2021; weak 2022 guidance, but it isn’t an investment case spoiler
- Published:
02 Mar 2022 -
Author:
Anas PATEL -
Pages:
4 -
bioMerieux ended 2021 on a healthy note, with impressive sales and profitability, driven by promising dynamics across segments. This also resulted in impressive dividend growth. While 2022 guidance was on the weaker side – due to fading COVID-19 testing tailwinds, and increasing costs (partly also due to post-pandemic normalisation), it wasn’t a big surprise. While our estimates could reset marginally lower, the sell-off in recent months opens an attractive opportunity, also with respect to M&A ....